Lure-and-kill macrophage nanoparticles alleviate the severity of experimental acute pancreatitis

Summary

This preclinical study targets phospholipase A2, a pathogenic trigger implicated in acute pancreatitis, with a biomimetic particle that combines attraction and inhibition. Polymeric cores were wrapped in natural macrophage membrane and supplemented with melittin plus MJ-33. In the design, membrane lipids and melittin attract PLA2 toward the nanoparticle, while MJ-33 inhibits the enzyme after engagement. The formulation neutralized PLA2 activity in serum from both mice and people with acute pancreatitis in a dose-dependent fashion and correspondingly suppressed PLA2-driven inflammatory responses. In mouse models representing mild and severe disease, treatment reduced inflammation and tissue injury and protected against lethality. The principal finding is that concentrating a pathogenic enzyme at an inhibitor-bearing membrane interface can turn the nanoparticle into an active sink rather than a passive drug carrier. The study is significant because it addresses an upstream disease mediator through coordinated biomimetic binding and enzymatic blockade, and the general logic could apply to other PLA2-mediated inflammatory disorders. The abstract supports biochemical activity and animal benefit, but it does not establish clinical efficacy, identify human dosing, or resolve the broader uncertainty surrounding acute-pancreatitis mechanisms.